IDO Modulators Inhibit Immunosuppression via Tryptophan Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IDO-related diseases such as cancer, viral infections, and autoimmune disorders are limited by the immunosuppressive effects of indoleamine 2,3-dioxygenase (IDO), which impede effective T-cell activation and tumor rejection, and there is a need for therapeutic agents that can modulate IDO activity to enhance immune responses.
Innovation Solution
Development of compounds that inhibit IDO activity, specifically those with Formula I structures, which can be administered to modulate enzyme activity and alter extracellular tryptophan levels, thereby inhibiting immunosuppression and treating associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IDO activity is increased to enhance antimicrobial effector mechanism and tumor rejection, then immune response effectiveness is improved, but T-cell activation is inhibited and immunosuppression is enhanced
Solution Approach 1:
The patent applies parameter changes by developing compounds that modulate IDO activity through chemical interaction. The inhibitors alter the enzymatic parameters of IDO, changing its catalytic efficiency and substrate binding characteristics. This allows selective modulation of IDO function to enhance antimicrobial responses while reducing immunosuppressive effects, thereby resolving the contradiction between immune effectiveness and T-cell activation.
2Reliability
If IDO activity is increased to deplete tryptophan and arrest pathogen growth, then antimicrobial efficacy is improved, but tryptophan depletion leads to cachexia, dementia and immunosuppression
Solution Approach 1:
The patent introduces intermediary compounds that act as modulators between IDO and its substrates. These compounds interfere with the IDO-catalyzed degradation of tryptophan, preventing excessive tryptophan depletion while maintaining sufficient antimicrobial effector mechanisms. The intermediaries restore tryptophan levels to physiologically appropriate ranges, thereby preventing cachexia and immunosuppression associated with complete tryptophan depletion.
3Reliability
If IDO is inhibited to enhance T-cell activation and improve immune responses, then antitumor activity is improved, but IDO inhibition may have off-target effects and limited specificity
Solution Approach 1:
The patent applies local quality by developing IDO modulators with specific structural characteristics that enable selective interaction with IDO in particular cellular contexts. The compounds exhibit different binding affinities and regulatory effects in tumor cells versus normal cells, allowing localized enhancement of antitumor activity while minimizing off-target effects. This selective modulation achieves improved antitumor responses without the complexity of multi-target therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit IDO activity, enhancing T-cell activation, improving immune responses, and treating conditions like cancer, viral infections, and autoimmune disorders by altering tryptophan metabolism, thus overcoming the immunosuppressive effects of IDO.
Implementation Method 1
The enzyme indoleamine 2,3-dioxygenase (also known as INDO or IDO) catalyzes the first and rate limiting step in the degradation of L-tryptophan to N-formyl-kynurenine. IFN-γ stimulation induces activation of IDO, which leads to a depletion of Trp
Data Source
AI summary
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.